| Document Date: 2014-10-01 21:56:22
Open Document File Size: 38,05 KBShare Result on Facebook
Company Medical Oncology Group of Australia / Janssen-Cilag Pty Ltd / The PBAC / Australian-Refined Diagnosis Related Group / / Country Australia / / Currency USD / / Event Reorganization / Product Recall / Product Issues / / IndustryTerm clinical management algorithm / treatment of metastatic advanced prostate cancer / / MedicalCondition resistant metastatic carcinoma / disease / metastatic advanced prostate cancer / progressive disease / neutropenia / febrile neutropenia / resistant prostate cancer / prostate cancer / / MedicalTreatment chemotherapy / intravenous infusion / / Organization World Health Organization / / Position Governor / nurse / / Product Abiraterone / prednisolone / CSF / prednisone / / Technology chemotherapy / clinical management algorithm / / URL http /
SocialTag |
PUBLIC SUMMARY DOCUMENT Product: Abiraterone, tablet, 250 mg (as acetate), Zytiga® Sponsor: Janssen-Cilag Pty Ltd Date of PBAC Consideration: November[removed]Purpose of Application